Sarepta agrees to FDA’s black box warning and announces major restructuring, including job cuts and cost-saving measures to meet 2027 goals.
Latest Ratings for SRPT
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Morgan Stanley | Maintains | Equal-Weight | |
| Mar 2022 | RBC Capital | Maintains | Outperform | |
| Feb 2022 | Morgan Stanley | Maintains | Equal-Weight |
